Clinical Indication ID & Name
Pancreatic Cancer
Test Group
Solid Tumours (Adult)
Specialties
Test code
M219.1
Test name
Multi-target NGS panel - small variant (BRCA1, BRCA2)
Target genes
BRCA1, BRCA2
Test scope
Small variant detection
Test method/ technology
Panel
Optimal Family Structure
n/a
Eligibility Criteria
Patient’s clinical status and local availability mean they can access a PARP inhibitor in the event a gBRCA mutation is detected
Test code
M219.2
Test name
Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3)
Target genes
NTRK1, NTRK2, NTRK3
Test scope
Structural variant detection
Test method/ technology
Panel
Optimal Family Structure
n/a
Eligibility Criteria
Patient’s clinical status means they are eligible for an NTRK inhibitor in the event an NTRK rearrangement is detected
Test code
M219.3
Test name
DPYD hotspot
Target genes
DPYD
Test scope
Small variant detection
Test method/ technology
Simple targeted mutation testing
Optimal Family Structure
n/a
Eligibility Criteria
Patient planned to receive fluoropyrimidine treatment
Test code
M219.5
Test name
MSI Testing
Target genes
N/A
Test scope
Microsatellite instability analysis
Test method/ technology
Microsatellite instability analysis
Optimal Family Structure
n/a
Eligibility Criteria
Known pancreatic cancer, when MMR IHC not possible / not performed, as per NICE Guidelines for molecular testing to inform therapy choice. Delivery via pathology in some regions.
Commissioning group
n/a
Overlapping idications
n/a
Address for samples/request forms
North Thames GLH, Rare & Inherited Disease Genomic Laboratory
Specimen Reception, Level 5 Barclay House, 37 Queen Square,
London WC1N 3BH
Contact with queries
Supporting documents
Cancer WGS Clinician pack
Education resources
n/a
Service updates
n/a
Request form download
Consent record
See consent guidance in test request form
Sample requirements
See sample guidance in test request form